Drug Trial Radar · NCT05513742
A Study of CTX-009 in Adult Patients With Metastatic Colorectal Cancer
Last checked: Nov 19, 2026Latest source record: Sep 25, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
49
Actual
Start
Dec 8, 2022
Primary completion
May 15, 2025
Study completion May 15, 2025
Sponsor
- Lead sponsor
- Compass TherapeuticsIndustry
- Sponsor type
- Industry
- First posted
- Aug 24, 2022
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is designed as an open-label, adaptive Simon Two-Stage study to evaluate the efficacy of CTX-009 in patients with metastatic colorectal cancer. A Simon Two-Stage adaptive design will enroll approximately 37 patients into Stage 1, and if criteria are met to move to Stage 2, an additional 47 patients will be enrolled.
Conditions
- Metastatic Colorectal Cancer
- Colon Cancer
- Rectal Cancer
Interventions
CTX-009Drug
IV infusion administered on day 1 and 15 of every 28-day cycle
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall Response RateTime frame: From first dose of CTX-009 until treatment discontinuation (an average of 16 weeks)
Locations
7 sites in 1 country. Site status is shown where the registry gives one.
Genesis Cancer and Blood Institute
Hot Springs, Arkansas
Florida Cancer Specialists & Research Institute - South
Fort Myers, Florida
Florida Cancer Specialists & Research Institute - North
St. Petersburg, Florida
Rutgers Cancer Institute of New Jersey
New Brunswick, New Jersey
Zangmeister Cancer Center
Columbus, Ohio
SCRI Oncology Partners
Nashville, Tennessee
Mary Crowley Cancer Research
Dallas, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.